Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NLA Nasal Spray - Meda

X
Drug Profile

NLA Nasal Spray - Meda

Alternative Names: NCX-1510; Nitric oxide-releasing cetirizine liposomal - Orexo; NLA; NO-releasing cetirizine liposomal - Orexo; OX-NLA

Latest Information Update: 29 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NicOx
  • Developer Meda
  • Class Acetic acids; Antiallergics; Benzyl compounds; Chlorobenzenes; Eye disorder therapies; Nonsedating antihistamines; Piperazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic rhinitis

Most Recent Events

  • 09 Mar 2012 Clinical development is ongoing in Sweden
  • 14 Apr 2008 Orexo's cetirizine-based nasal spray licensed worldwide to Meda
  • 18 Mar 2008 Adverse events data from a trial in allergic rhinitis released by Orexo
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top